Ebenezer (@BackwaterBio) profile picture

Private biotech

Joined February 2016
Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)Photo by Ebenezer (@BackwaterBio)
Ebenezer retweeted
wtf now my agents found the first bacteria to use new stop codons!! After this TAG result, a chat w/ friend inspired the question: do any bacteria use other stop codons? Overnight, my guys found myxobacteria that stop at TTA, normally read as an amino acid. Evidence: 1) These bacteria lost the tRNA that normally reads TTA as leucine. 2) Their RF2, the protein that recognizes stop codons, has two changes: one in its codon-reading tip (SPF → SPY) and one nearby (L → F). No other species in GTDB has both. 3) We compared the same genes in these bacteria and their closest relatives. Where a relative's gene ends at a normal stop but the gene here keeps going, the very next codon is TTA 11% of the time (252 of 2,339 genes). In the relatives, it's 0.05% (1 of 2,025). 4) TTA swaps with the normal stop codons. Where one of these genomes ends a gene at TTA, another genome from the same group ends that gene at a normal stop 78% of the time. Method: Claude agents on my Mac mini scanned all 199,923 bacterial and archaeal genomes in GTDB for amino-acid codons unusually common near the ends of genes, where a hidden stop would sit. In 4,599 genomes, they then matched each gene to corresponding proteins and checked which codon sits exactly where the known protein ends. Closest prior work: TTA works as a stop in some mitochondria and plastids (Barcytė et al. 2025), and CGA was proposed as a stop in Asgard archaea (Melnykov 2026, PNAS), but none in bacteria until now. One of these bacteria, 1-FT3.2, is kept alive in Finland (Demina et al. 2025). Possibly its proteins can be measured to confirm this.
I discovered the first bacteria that no longer use TAG as a stop codon. Almost all life ends its genes with the same 3 "stop" signals: TAA, TAG and TGA. Bacteria were known to reassign TGA since the 80s. Archaea reassigning TAG was published in Science last year. 🧬 1/n
11
39
8
268
44,752
Introducing Helios: measuring 1,000+ protein biomarkers from a drop of blood to help you live younger, longer. Here’s how it works: • Self-collect blood at home with a painless, needle-free device • We measure the proteins carrying signals from cells and organs throughout your body • Your Helios AI agent explains your results, highlights risks, and offers personalized guidance Proudly backed by Y Combinator and Formation VC. Join the waitlist at myhelios.com
438
459
210
3,684
1,854,553
You mean you don't appreciate when your biotech holding with fantastic data is up 40% in the premarket with 50% more upside to fair value, and then gets crushed to flat at open because risk at a large MM market sold a pod's holdings for blowing up on a MRNA short position, and then a quant momentum strategy shorts it because of the big pullback, and then a quant fund piles on the selling pressure by hedging their AI long trade by shorting interest rate risk out with a SMID cap biotech short, and then the stock is down 15% and no one knows why so an analyst publishes that obviously the stock is down because (pick random datapoint that doesn't matter) but in reality was just persuaded on a call with a pod PM to be bearish because they had a short position they needed to press and then that narrative gets entrenched and you're sitting here wondering why this company swung 60% down on great data and is financed through CF+ and trades at a big discount to some other biotech company and the world moves on to the next company with data tomorrow and no one cares to re-visit your company because it's a "catalyst desert" for 3 months? And pharma then passes over it and buys an undifferentiated pre-clinical private China asset instead of your company, which blows up on them a year later and they write it down but now your company needs to finance at a discount to the prior data? How could you not love that?
Replying to @pequityresearch
I miss the days when the price discovery was driven by good ol' fashion fundamental analysis. All quant algos and retail now fucking everything up.
47
80
20
982
97,057
13F season is back, which means another round of “BUFFETT BOUGHT X” or “CITADEL LOADED UP ON X” headlines. Most are familiar with/ the 45-day lag, quarter-end snapshots, and the multitude of positions types/ exposures excluded from filings. One thing I’ve noticed gets far less attention is that 13Fs reflect aggregate holdings across a firm's various funds and strategies. This is particularly relevant for multi-strats like Citadel, which have dozens of underlying strategies, PMs, and quant-driven books. Even healthcare/biotech specialists, which tend to offer a somewhat clearer picture, often manage several strategies beyond their original flagship fund, ranging from long-only and crossover to private/venture. Redmile is a good example. Looking at its Form ADV gives you an idea of how many different pools of capital can sit behind a single manager's 13F. Something to keep in mind when interpreting quarterly position changes or trying to infer a manager's conviction in a particular stock.
1
1
14
1,486
$ACRS unfortunately another anti-TSLP failure in AD: Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) ADMIRATION Trial Did Not Achieve its Primary Endpoint TSLP key role in activating Tregs may be the problem, I continue to be wary on this target investor.aclaristx.com/news-…
Continuing pressure in Anti-#TSLP space for small bios $UPB $CLDX, not sure if $ACRS or $APGE will also be affected. Weakness has been since paper showing relationship between #Tregs and TSLP last month.
1
3
1
27
4,441
Happy #JefferiesHealthcare to all who celebrate
NEW from @FT: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4bn, the latest in a glut of bolt-on acquisitions in the biotechnology sector.
2
8
40
6,225
Ebenezer retweeted
1/ New Lux LP letter. Q3 2026: "Anomalous Instruments"
6
28
7
216
54,110
Comprehensive list of hedge funds blowing up this week, getting large redemptions, or shutting down PMs: - Axebrook - Walleye - Engineers Gate - Lone Pine - Millennium internal pods - Verition pods - Samlyn Letter from Walleye closing internal funds below
89
511
221
2,677
752,340
Ebenezer retweeted
AI hyperbole has consequences. "AI will take 50% of jobs" & "AI will cure cancer" are both overstatements. The positive overstatement promotes investor excitement, & the negative fear in citizens. Combination is dangerous concoction driving a simultaneous bubble & revolution.
‘“That’s complete BS,” said Jeff Leiden, executive chairman of Vertex Pharmaceuticals. Vertex has used roughly 50 AI companies to comb through its data set of 10,000 drug compounds, Leiden said. Not one managed to generate a working drug.’ 👇🏼 wsj.com/tech/ai/silicon-vall…
72
53
11
383
53,200
The Singularity is coming for Physics and Biology. RIP Math.
105
652
113
6,874
642,957
Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All
533
1,067
388
14,425
1,770,318
“infinite compute can’t help you simulate a system that’s never even been observed or measured” the most eloquent explanation to why ai ain’t solving aging in the current status quo
Am I missing something? Where do the inputs to train this simulation come from? Compute is not the bottleneck in biology. It’s estimated we have only sequenced genomes for 1% of eukaryotic species, and DNA is just the beginning. Infinite compute can’t help you simulate a system that’s never even been observed or measured.
5
3
2
87
2,979
Ebenezer retweeted
I’m not sure I understand how this would work. If you put limitations on investments from US entities, doesn’t that just channel those investments through non-US entities? Either way it doesn’t prevent those molecules from entering US trials and outcompeting US-funded ones
2
1
8
1,219
One month (or so) on @X , a platform unlike any other. Energy, speed, smarts and stupidity. -The best thing in BioX - Rapid and divergent takes on new clinical data, on balance usually right..wisdom of crowds -The worst thing on BioX - Shameless replies and reposts pumping your own book, praying for M&A about your favorite name, plane stalking…do people actually think this is how a real drug company or serious investor makes decisions? Maybe it just makes you feel like you have some agency, then ok.
111
55
72
758
184,812
How it began, £5m market cap on the good old AIM market $XBI $SLN
51
19
9
495
413,773
Ebenezer retweeted
Going to get this quote framed and hang it up in my apartment like one of those Live Laugh Love signs
Matt Gline, Roivant CEO, on Anthropic's foray into biotech:
1
23
1
304
16,476
Ebenezer retweeted
This is an insane excerpt from the FT article lmao
NEWS: SpaceX is planning to raise $40 billion in debt financing led by Apollo to purchase Nvidia AI chips.
45
88
13
2,050
141,222
Ebenezer retweeted
Many of you have been asking us: "Who is Approved?" "Where is Approved?" and even, sometimes… "Why is Approved?" Rather than let this mystery haunt us any longer, here is our official breakdown of what this podcast covers. Check it out:
6
16
5
108
32,431
A reminder that nobody has done the reading, and if you do that alone you’ll soon find yourself absurdly ahead of the curve
76
829
95
10,315
720,989
Ebenezer retweeted
Simulating the consequences of an experiment before running it is a holy grail of AI for biology. How can we get there? Our new paper, “World models for biomedicine,” which I led together with @njwfish, is out now in @CellCellPress’s special issue on AI in biology. We explore how biomedical world models could help scientists navigate the enormous space of possible biological interventions. In principle, they could: 🧪 Simulate how biological systems respond to interventions never previously tested 🎯 Search for interventions that drive cells, tissues, or patients toward desired states 🧭 Plan experimental campaigns over long time horizons 🤖 Power autonomous, closed-loop AI scientists However, realizing this vision requires much more than calling a model a “world model.” What exactly defines a biomedical world model, and what capabilities distinguish it from related models? Where do today’s models already show promise, and where do they fall short? What new data and architectures are needed? What evaluations would demonstrate that a world model works? We tackle these and other questions in this latest paper from @marinkazitnik's lab: cell.com/cell/fulltext/S0092… More below 🧵👇🏽 1/8
22
55
9
282
19,544